DOJ lawsuit charges Regeneron with inflating Medicare costs
By 
Jeff Dale2024-04-11T20:57:00
New York-based Regeneron Pharmaceuticals, manufacturer and seller of the macular degeneration drug Eylea, is being sued by the Department of Justice (DOJ) for allegedly flouting Medicare’s price reporting requirements.
Regeneron failed to report applicable price concessions in the form of credit card processing fees to the Centers for Medicare and Medicaid Services (CMS), the DOJ claimed in a press release Wednesday.
The lawsuit was originally filed under the qui tam provisions of the False Claims Act by two former Regeneron employees. The United States intervened in the case, which is permitted under the act. If found liable, Regeneron could pay treble damages, plus penalties.
Related articles
-
News BriefDOJ orders Houston medical centers to pay $15M over concurrent billing false claims
Houston-based medical center institutions agreed to jointly pay $15 million to settle allegations for improperly billing Medicare for concurrent surgeries in violation of teaching physician and informed consent regulations.
-
News BriefBluestone Physician Services to pay $14.9M in false claims case
Bluestone Physician Services agreed to pay approximately $14.9 million and abide by a corporate integrity agreement to settle allegations that it filed false claims to federal and state health programs for chronic pain care to people in assisted living facilities.
-
News BriefConsolidated Nuclear Security to pay $18.4M over timecard false claims
Consolidated Nuclear Security agreed to pay $18.4 million to settle alleged False Claims Act violations regarding the submission of timecards for unworked hours to the National Nuclear Security Administration.
More from Regulatory Enforcement
-
News BriefDOJ clears $4.4 Billion T‑Mobile acquisition of UScellular
The U.S. Department of Justice arppoved T-Mobile’s acquisition of competitor UScellular. The move came a day after T-Mobile announced it had dropped its diversity, equity, and inclusion programs, a frequent target for Trump’s administration.
-
News BriefFlorida alleges that Robinhood Crypto’s fee disclosures are inaccurate
The state of Florida is investigating Robinhood Crypto for falsely claiming it charges the lowest fees for processing crypto transactions.
-
News BriefCVS hit with nearly $1 billion fine in Omnicare false claims verdict
CVS has vowed to appeal $948.8 million in fines and damages imposed by a judge Tuesday on its Omnicare unit, for billing Medicare for tens of thousands of false claims.